Skip to main content
Assets
Merck & logo
MRK.NYSE
Merck &
Health Care · Pharmaceuticals

Global healthcare company providing medicines and vaccines for oncology, vaccines, hospital acute care, and animal health including Keytruda.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Merck &.

Historical AI Opinions

Merck & Co., Inc. (MRK.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 12 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+45.1%

Includes 1.68% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.61.2486.13111.02135.91160.8Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$112+7.5%Not Generated this time
$117+11.7%Not Generated this time
$115+9.5%Not Generated this time
$119+13.9%Not Generated this time
$117+12.2%Not Generated this time
$122+16.5%Not Generated this time
$126+20.8%Not Generated this time
$131+25.2%Not Generated this time
$135+29.4%Not Generated this time
$140+33.6%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

The most reasonable thesis posits that Merck is currently undervalued at $104.63, reflecting excessive fear regarding the 2028 Keytruda patent cliff. While the LOE is a genuine headwind, Merck's pipeline diversification is underestimated. Winrevair is likely to see steady, strong adoption, becoming a foundational driver. The subcutaneous Keytruda option will likely secure approval, retaining a significant portion of the franchise's value, though not all. The Daiichi Sankyo ADC partnership and internal oncology pipeline will fill revenue gaps, allowing for low-single-digit revenue growth through the cliff years rather than a contraction. The stock will likely grind higher as confidence rebuilds, driven by consistent earnings beats, dividend growth, and a gradual expansion of the P/E multiple back to historical norms of 13-14x.

2. Scenarios & Signals

2.1. Bull Case

In this scenario, Merck executes a flawless 'soft landing' for the Keytruda franchise. The subcutaneous formulation (SC) receives broad FDA approval with favorable patent exclusivity extending into the 2030s, effectively converting 50%+ of the intravenous volume and mitigating the 2028 patent cliff. Concurrently, Winrevair (sotatercept) significantly outperforms consensus, becoming a $6B+ peak revenue megablockbuster by 2028. The ADC collaboration with Daiichi Sankyo yields two best-in-class assets that rapidly gain market share in lung and breast cancer. Macroeconomically, a rotation back into high-quality defensive value stocks with strong dividends favors Merck. The market re-rates MRK from a 10-11x P/E to a 15-16x multiple as revenue visibility clears past 2028, driving the stock toward new all-time highs above $160.

2.2. Bear Case

In the bear case, the 2028 Loss of Exclusivity (LOE) for Keytruda proves catastrophic. Competitors flood the market with biosimilars faster than anticipated, and the subcutaneous defensive strategy faces regulatory setbacks or limited payer reimbursement, leading to a steep revenue drop. Winrevair uptake is hampered by safety monitoring requirements or slow payer access, capping peak sales below $2B. The Inflation Reduction Act (IRA) aggressively targets Keytruda and Januvia, compressing margins earlier than modeled. Pipeline assets, including the Daiichi ADCs, experience clinical delays or fail to differentiate in a crowded oncology market. Investors view Merck as a 'value trap' with shrinking earnings, compressing the valuation multiple to single digits (8-9x P/E) and pinning the stock in the $80-$90 range.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 3,095Thinking Tokens: 1,580Response Tokens: 7,549Total Tokens: 12,224
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.